These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. AMPA Receptor Dysregulation and Therapeutic Interventions in a Mouse Model of CDKL5 Deficiency Disorder. Yennawar M; White RS; Jensen FE J Neurosci; 2019 Jun; 39(24):4814-4828. PubMed ID: 30952813 [TBL] [Abstract][Full Text] [Related]
4. CDKL5 deficiency in forebrain glutamatergic neurons results in recurrent spontaneous seizures. Wang HT; Zhu ZA; Li YY; Lou SS; Yang G; Feng X; Xu W; Huang ZL; Cheng X; Xiong ZQ Epilepsia; 2021 Feb; 62(2):517-528. PubMed ID: 33400301 [TBL] [Abstract][Full Text] [Related]
5. Cannabidiol attenuates seizure susceptibility and behavioural deficits in adult CDKL5 Li X; Yennawar M; Wiest A; O'Brien WT; Babrowicz B; White RS; Talos DM; Jensen FE Eur J Neurosci; 2024 Jun; 59(12):3337-3352. PubMed ID: 38654472 [TBL] [Abstract][Full Text] [Related]
11. Expanding the phenotype of the CDKL5 deficiency disorder: Are seizures mandatory? MacKay CI; Bick D; Prokop JW; Muñoz I; Rouse J; Downs J; Leonard H Am J Med Genet A; 2020 May; 182(5):1217-1222. PubMed ID: 32034940 [TBL] [Abstract][Full Text] [Related]
12. A GABA Gennaccaro L; Fuchs C; Loi M; Roncacè V; Trazzi S; Ait-Bali Y; Galvani G; Berardi AC; Medici G; Tassinari M; Ren E; Rimondini R; Giustetto M; Aicardi G; Ciani E Neurobiol Dis; 2021 Jun; 153():105304. PubMed ID: 33621640 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of microglia overactivation restores neuronal survival in a mouse model of CDKL5 deficiency disorder. Galvani G; Mottolese N; Gennaccaro L; Loi M; Medici G; Tassinari M; Fuchs C; Ciani E; Trazzi S J Neuroinflammation; 2021 Jul; 18(1):155. PubMed ID: 34238328 [TBL] [Abstract][Full Text] [Related]
14. Early-onset brain alterations during postnatal development in a mouse model of CDKL5 deficiency disorder. Tassinari M; Uguagliati B; Trazzi S; Cerchier CB; Cavina OV; Mottolese N; Loi M; Candini G; Medici G; Ciani E Neurobiol Dis; 2023 Jun; 182():106146. PubMed ID: 37164289 [TBL] [Abstract][Full Text] [Related]
16. Pharmacotherapy with sertraline rescues brain development and behavior in a mouse model of CDKL5 deficiency disorder. Fuchs C; Gennaccaro L; Ren E; Galvani G; Trazzi S; Medici G; Loi M; Conway E; Devinsky O; Rimondini R; Ciani E Neuropharmacology; 2020 May; 167():107746. PubMed ID: 31469994 [TBL] [Abstract][Full Text] [Related]
17. Molecular and Synaptic Bases of CDKL5 Disorder. Zhu YC; Xiong ZQ Dev Neurobiol; 2019 Jan; 79(1):8-19. PubMed ID: 30246934 [TBL] [Abstract][Full Text] [Related]
18. Dopaminergic loss of cyclin-dependent kinase-like 5 recapitulates methylphenidate-remediable hyperlocomotion in mouse model of CDKL5 deficiency disorder. Jhang CL; Lee HY; Chen JC; Liao W Hum Mol Genet; 2020 Aug; 29(14):2408-2419. PubMed ID: 32588892 [TBL] [Abstract][Full Text] [Related]
19. Luteolin Treatment Ameliorates Brain Development and Behavioral Performance in a Mouse Model of CDKL5 Deficiency Disorder. Tassinari M; Mottolese N; Galvani G; Ferrara D; Gennaccaro L; Loi M; Medici G; Candini G; Rimondini R; Ciani E; Trazzi S Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955854 [TBL] [Abstract][Full Text] [Related]
20. CDKL5 deficiency disorder in males: Five new variants and review of the literature. Siri B; Varesio C; Freri E; Darra F; Gana S; Mei D; Porta F; Fontana E; Galati G; Solazzi R; Niceta M; Veggiotti P; Alfei E Eur J Paediatr Neurol; 2021 Jul; 33():9-20. PubMed ID: 33989939 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]